Myasthenia gravis (MG) is a chronic autoimmune disorder that causes muscle weakness and fatigue due to the immune system producing antibodies that disrupt nerve-muscle communication. A severe manifestation of this condition, known as myasthenic …
Myasthenia Gravis (MG) is a chronic autoimmune disorder that causes muscular weakness, particularly affecting voluntary muscles involved in swallowing, leading to dysphagia. Dysphagia in MG can manifest as difficulty swallowing, painful swallowing, …
Myasthenia gravis (MG) is a chronic autoimmune disorder that causes muscle weakness and fatigue affecting voluntary muscles, which worsen with activity and improve with rest. This condition significantly impacts daily life, including personal …
Myasthenia gravis (MG) is an autoimmune disorder that causes muscle weakness, particularly affecting communication and swallowing. Symptoms often include drooping eyelids, double vision, altered facial expressions, and speech difficulties such as …
Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by significant muscle weakness, particularly affecting voluntary muscles involved in eye movement, facial expressions, swallowing, and breathing. The condition arises when the …
Muscle twitching refers to involuntary contractions of muscles, commonly seen in areas like the eyelids, calves, and thumbs. These twitches result from the activation of motor units within the nervous system and can be triggered by factors such as …
Dermatomyositis and polymyositis are inflammatory myopathies characterized by muscle inflammation and weakness. Dermatomyositis includes distinctive skin rashes, while polymyositis affects muscle fibers without skin involvement. Both conditions can …
Myasthenia gravis (MG) is a rare autoimmune neuromuscular disorder that causes muscle weakness and fatigue, primarily due to antibodies blocking acetylcholine receptors at the neuromuscular junction. The condition commonly affects women under 40 and …
Myasthenia Gravis (MG) is a chronic autoimmune disorder causing muscle weakness due to disrupted communication between nerves and muscles, primarily affecting young women under 40 and older men over 60. The condition may involve genetic and …
Vyvgart (efgartigimod alpha-fcab) is a novel biologic medication approved by the FDA in December 2022, specifically for treating generalized myasthenia gravis (gMG), an autoimmune disorder. It functions by targeting and reducing the activity of the …
Rystiggo (rocuronium bromide) is a neuromuscular blocking agent used primarily for managing neuromuscular disorders like Myasthenia Gravis (MG), which causes muscle weakness due to impaired nerve communication. It facilitates muscle relaxation by …
Vyvgart (efgartigimod alfa) is a novel treatment for myasthenia gravis (MG), an autoimmune disorder that leads to muscle weakness. It works by targeting and inhibiting the neonatal Fc receptor (FcRn), reducing pathogenic IgG antibodies that interfere …
